Department of Internal Medicine, University Hospital, 12 de Octubre, Avenida de Córdoba s/n, 28041, Madrid, Spain.
Research Institute I+12, University Hospital, 12 de Octubre, Avenida de Córdoba s/n, 28041, Madrid, Spain.
Orphanet J Rare Dis. 2021 May 31;16(1):243. doi: 10.1186/s13023-021-01878-2.
Tuberous sclerosis (TS) is a condition whose manifestations in childhood have been extensively described, but whose presentation in adults is less well known. This study describes the clinical and genetic characteristics, therapeutic management and quality of life of a cohort of adult patients with TS. A comparative study of the characteristics of patients diagnosed in childhood and adulthood is also carried out.
This observational, retrospective, cross-sectional study included a large cohort of adult patients (≥ 16 years old) followed for 5 years in a specific rare diseases unit.
Fifty-seven patients with a diagnosis of tuberous sclerosis were included, more than 50% of whom were diagnosed as adults. The mean age of the patients was 42 years (20-86). The central nervous system was the main area affected (97%), followed by the skin (80.7%) and kidneys (73%). The most frequent genetic alteration was a mutation in the TSC2 gene (47.7%). Among patients diagnosed in adulthood, there was less neurological involvement, with less frequency of epileptic seizures (30.8% vs 60.79% of patients diagnosed in childhood) and astrocytomas (3.8% vs 53.6%), less intellectual disability (11.5% vs 71.4%) and less expressiveness of the condition. 42% of patients were treated with mTOR pathway inhibitors, and presence of an angiomyolipoma was the main indication. In a quality-of-life analysis, the means of the summary indices were below the scores of the average Spanish population: (47.42 (SD ± 9.82) on the physical health scale, 45.61 (SD ± 7.99) on the mental health scale) versus 50 (SD ± 10) for the general population.
Up to 50% of adult patients with TS were diagnosed in adulthood, and the condition is less severe with less frequent epileptic seizures and intellectual disability. 42% require treatment with mTOR inhibitors, in most cases due to the presence of AMLs. The quality of life of adult patients with TS is diminished compared to the general population.
结节性硬化症(TS)是一种在儿童期表现已被广泛描述的疾病,但在成人中的表现却鲜为人知。本研究描述了一组 TS 成年患者的临床和遗传特征、治疗管理和生活质量。还对在儿童期和成年期诊断的患者的特征进行了比较研究。
这项观察性、回顾性、横断面研究纳入了一个在特定的罕见疾病单位中接受了 5 年随访的大量成年患者(≥16 岁)。
共纳入 57 例 TS 诊断患者,其中超过 50%的患者在成年期被诊断。患者的平均年龄为 42 岁(20-86 岁)。中枢神经系统是最主要的受累部位(97%),其次是皮肤(80.7%)和肾脏(73%)。最常见的基因改变是 TSC2 基因突变(47.7%)。在成年期诊断的患者中,神经系统受累较少,癫痫发作频率较低(30.8%与儿童期诊断的患者相比为 60.79%)和星形细胞瘤较少(3.8%与儿童期诊断的患者相比为 53.6%),智力残疾较少(11.5%与儿童期诊断的患者相比为 71.4%)和疾病表达性较少。42%的患者接受了 mTOR 通路抑制剂治疗,血管平滑肌脂肪瘤的存在是主要指征。在生活质量分析中,综合指数的平均值低于西班牙普通人群的分数:(生理健康量表 47.42(SD±9.82),心理健康量表 45.61(SD±7.99))与普通人群的 50(SD±10)相比。
多达 50%的 TS 成年患者在成年期被诊断,病情较轻,癫痫发作和智力残疾的频率较低。42%的患者需要接受 mTOR 抑制剂治疗,大多数情况下是因为存在 AML。与普通人群相比,TS 成年患者的生活质量下降。